title: Recombinant human interferon gamma (Gamma Immunex) in treatment of atopic dermatitis.
abstract: Atopic dermatitis (AD) is a chronic, inflammatory skin disease which is characterized by severe pruritus and affects patients' quality of life. In recent years gamma interferon (IFN-gamma) has been accepted as a novel treatment for severe AD, however, its mechanism of action is not clearly identified. Present study evaluated the effect of recombinant human interferon gamma (rIFN-gamma: Gamma Immunex, Exir Pharmaceutical Company, Iran) on severity of AD (SCORAD), dermatology life quality index (DLQI) as well as serum levels of IL-4, IgE and IL-6 in AD patients. Twenty AD patients were entered in to a study in Baqiyatallah outpatient clinics and received rIFN-gamma (50 μg/m(2) body area, 3 times per week, subcutaneously) for 1 month. SCORAD and DLQI were assessed at beginning and end of the treatment period. IL-4, IL-6 and IgE were measured in blood samples before and after 1 month treatment with rIFN-gamma. DLQI mean value before treatment was 20.80 ± 3.95, which decreased to 8.20 ± 2.14 after treatment (P < 0.001). SCORAD-A (percentile of the body surface involved in AD), SCORAD-B (the severity of clinical features) and SCORAD-C (patients' scaling of itching and somnolence) significantly decreased after treatment (P < 0.001, P < 0.001 and P < 0.01). Total SCORAD at the end of treatment period was less than basal value (27.83 ± 8.48 vs. 70.04 ± 8.48; P < 0.001). Treatment with rIFN-gamma decreased serum levels of IL-4 and IL-6 (P < 0.05), but IgE remained unchanged. Results suggested the controlling effect of rIFN-gamma treatment on clinical symptoms of AD, which involves suppression of IL-4 but not IgE production.
authors.affiliation: Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. yunespanahi@yahoo.com
authors.forename: Yunes
authors.initials: Y
authors.lastname: Panahi
authors.forename: Seyyed Masoud
authors.initials: SM
authors.lastname: Davoudi
authors.forename: Nima
authors.initials: N
authors.lastname: Madanchi
authors.forename: Ehsan
authors.initials: E
authors.lastname: Abolhasani
mesh_terms: D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007167:Immunotherapy / Q000379:methods; D007371:Interferon-gamma / Q000008:administration & dosage*; D015847:Interleukin-4 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D007492:Iran; D011788:Quality of Life; D011994:Recombinant Proteins / Q000008:administration & dosage; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: C573415:IFNG protein, human; D015850:Interleukin-6; D011994:Recombinant Proteins; D015847:Interleukin-4; D007073:Immunoglobulin E; D007371:Interferon-gamma
references.citation: J Am Acad Dermatol. 1993 Feb;28(2 Pt 1):189-97
references.pmid: 8432915
references.citation: Br J Dermatol. 1994 Sep;131(3):406-16
references.pmid: 7918017
references.citation: Arch Dermatol. 1998 Jul;134(7):799-804
references.pmid: 9681342
references.citation: Br J Dermatol. 2007 Oct;157(4):645-8
references.pmid: 17714568
references.citation: Clin Exp Dermatol. 2007 Jan;32(1):23-7
references.pmid: 17059445
references.citation: Allergy. 1993 Apr;48(3):189-95
references.pmid: 8506987
references.citation: J Drugs Dermatol. 2010 May;9(5):488-98
references.pmid: 20480792
references.citation: Br J Dermatol. 1994 Sep;131(3):397-405
references.pmid: 7918016
references.citation: J Am Acad Dermatol. 2000 Jun;42(6):1033-40
references.pmid: 10827410
references.citation: Dermatol Ther. 2010 Jan-Feb;23(1):90-3
references.pmid: 20136913
references.citation: Clin Exp Dermatol. 2008 Nov;33(6):710-1
references.pmid: 18681884
references.citation: J Immunol. 2010 Mar 1;184(5):2729-35
references.pmid: 20107184
references.citation: Acta Derm Venereol. 1991;71(6):484-7
references.pmid: 1685830
references.citation: Ann Dermatol. 2010 Feb;22(1):9-15
references.pmid: 20548874
references.citation: J Invest Dermatol. 2005 Dec;125(6):1156-62
references.pmid: 16354185
references.citation: J Allergy Clin Immunol. 2006 Sep;118(3):725-33
references.pmid: 16950294
references.citation: Arch Dermatol Res. 2006 Jun;298(1):31-7
references.pmid: 16586073
references.citation: J Am Acad Dermatol. 1993 Jul;29(1):58-63
references.pmid: 8315079
references.citation: Clin Exp Dermatol. 1994 May;19(3):210-6
references.pmid: 8033378
references.citation: J Cutan Med Surg. 2003 Nov-Dec;7(6):467-73
references.pmid: 15926215
references.citation: J Invest Dermatol. 1998 Dec;111(6):1079-84
references.pmid: 9856820
references.citation: Am J Med. 2009 Feb;122(2):121-5
references.pmid: 19185084
references.citation: Acta Derm Venereol. 1989;69(1):41-5
references.pmid: 2563607
references.citation: Ann Allergy Asthma Immunol. 1998 Mar;80(3):263-8
references.pmid: 9532976
references.citation: J Allergy Clin Immunol. 1995 Jul;96(1):84-91
references.pmid: 7622767
references.citation: Pol Arch Med Wewn. 1994 Dec;92(6):499-506
references.pmid: 7716053
references.citation: Allergy. 1995 Jun;50(6):520-3
references.pmid: 7573848
references.citation: Br J Dermatol. 1994 Sep;131(3):383-96
references.pmid: 7918015
references.citation: Vet Dermatol. 2011 Feb;22(1):24-30
references.pmid: 20860556
references.citation: Am J Med. 1990 Apr;88(4):365-70
references.pmid: 2109531
references.citation: Am J Clin Dermatol. 2002;3(3):175-83
references.pmid: 11978138
references.citation: J Allergy Clin Immunol. 1992 Sep;90(3 Pt 1):323-31
references.pmid: 1527316